Neural Regeneration Research ›› 2021, Vol. 16 ›› Issue (9): 1764-1765.doi: 10.4103/1673-5374.306070

Previous Articles     Next Articles

Sex, ApoE4 and Alzheimer’s disease: rethinking drug discovery in the era of precision medicine

Manish D. Paranjpe#, Jason K Wang#, Yun Zhou*   

  1. Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, USA (Paranjpe MD, Wang JK)
    Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA (Zhou Y)
  • Online:2021-09-15 Published:2021-02-05
  • Contact: Yun Zhou, PhD, yunzhou@wustl.edu.

PDF

42

Abstract: Alzheimer’s disease (AD) is the most common cause of dementia and presents with an insidious onset and long prodromal period. Despite billions spent on clinical trials and decades of research, there are currently no disease modifying therapies approved for AD.